Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa...

FDA Recall #D-0387-2025 — Class II — April 14, 2025

Recall #D-0387-2025 Date: April 14, 2025 Classification: Class II Status: Ongoing

Product Description

Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-10

Reason for Recall

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Recalling Firm

Breckenridge Pharmaceutical, Inc — Berlin, CT

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

16,473 bottles

Distribution

US Nationwide.

Code Information

Lot # 240987C, exp. date 04/2027 241014C, exp. date 04/2027

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated